Adagio Medical reports zero sales and $3.1m cash while FDA weighs ablation device
The cardiac ablation company's US launch hinges on a pending regulatory decision with no disclosed date, as its board reviews options and it consolidates its shares.
Adagio Medical Holdings has no commercial revenue to show for the third quarter of 2026, and its only US route to market, a regulatory filing for its vCLAS system to treat ventricular tachycardia, is still with the Food and Drug Administration. The company gave the update with its results on 16 November.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Adagio Medical Holdings, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.